Friday, February 23, 2024
HomeFunding Switzerland-based Nouscom Secures €67.5M in Series C Round Funding

[Funding alert] Switzerland-based Nouscom Secures €67.5M in Series C Round Funding

Switzerland-based Nouscom secures €67.5M in series C round funding. Leading the round were Andera Partners, Bpifrance (via its InnoBio 2 fund), and M Ventures. Other participants included Revelation Partners, Panakès Partners, XGen Ventures, Indaco Venture Partners, and current investors Versant Ventures, EQT Life Sciences, and 5AM Ventures.

Switzerland-based Nouscom secures €67.5M in series C round funding. Leading the round were Andera Partners, Bpifrance (via its InnoBio 2 fund), and M Ventures. Other participants included Revelation Partners, Panakès Partners, XGen Ventures, Indaco Venture Partners, and current investors Versant Ventures, EQT Life Sciences, and 5AM Ventures.

Alongside the funding, members from M Ventures, Bpifrance, and Andera Partners joined the Nouscom Board of Directors. The business plans to use the money to fund the expansion and advancement of its fully owned clinical pipeline in order to accomplish certain clinical value catalysts, such as:

Read also – UK-based Accenture Acquire 6point6

Readout from a current randomised Phase 2 clinical trial for mismatch repair/microsatellite instabilities (dMMR/MSI) metastatic colorectal cancer (mCRC) using pembrolizumab and NOUS-209, an off-the-shelf vaccination targeting 209 common neoantigens.

The present report provides the final analysis of the current Phase 1b trial, which is examining the ability to intercept, prevent, or postpone cancer before it arises in Lynch Syndrome (LS) carriers by the use of NOUS-209 monotherapy.

Read also – SUPPLYZ Rebrands as RESONIKS and Secures Investment from Kvanted

LS carriers are more likely to acquire some cancers because to a genetic predisposition. At the most recent Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting, encouraging preliminary findings from this study were presented in a Late-breaking Abstract.

Nouscom, a clinical-stage immuno-oncology business led by CEO Marina Udier, is creating both customised and off-the-shelf cancer immunotherapies.

Read also – Chasse sur Rhône-based Recyc’ELIT Raises €3.2M in Funding

Its unique viral vector technology has been clinically shown to safely and potently stimulate the immune system while encoding for huge payloads of neoantigens or other immunomodulators.

About Nouscom

Additionally, VAC-85135, an off-the-shelf immunotherapy created under a multi-project agreement and presently being assessed in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms supported by Janssen Research & Development and Bristol Myers Squibb, is exclusively out-licensed by Nouscom.

Read also – London-based Letoon Holding Secures £20M in Funding

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular